Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2

Bone

Volumn 22, Issue 2, 1998, Pages 99-105

  Mori, S ^a   Yoshikawa, H ^a   Hashimoto, J ^b   Ueda, T ^a   Funai, H ^a   Kato, M ^c   Takaoka, K ^d  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c CANCER INSTITUTE   (Japan)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Bone formation; Bone morphogenetic protein; Mesenchymal cell; Pericyte; TNP 470

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN TYPE 1A RECEPTOR; CELL RECEPTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL PROLIFERATION; CHONDROGENESIS; CONTROLLED STUDY; DOSE RESPONSE; ENCHONDRAL OSSIFICATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYME CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSSIFICATION; OSTEOBLAST; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CHONDROCYTES; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESODERM; MICE; MICE, INBRED C3H; MUSCLE, SKELETAL; NEOVASCULARIZATION, PATHOLOGIC; OSTEOGENESIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, GROWTH FACTOR; RECOMBINANT PROTEINS; SESQUITERPENES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031964376     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(97)00248-2     Document Type: Article

References (20)

1. Abe J., Zhou W., Takuwa N., Taguchi J., Kurokawa K., Kumada M., Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. 54:1994;3407-3412.
2. Brighton C. T., Hunt R. M. Early histological and ultrastructural changes in medullary fracture callus. J Bone J Surg. 73-A:1991;832-847.
3. Brighton C. T., Lorich D. G., Kupcha R., Reilly T. M., Jones A. R., Woodbury R. A. Jr. The pericyte as a possible osteoblast progenitor cell. Clin Orthop. 275:1992;287-299.
4. Dewulf N., Verschueren K., Lonnoy O., Morén A., Grimsby S., Spiegle K. V., Miyazono K., Huylebroeck D., ten Dijke P. Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology. 136:1995;2652-2663.
5. Diaz-Florez L., Gutierrez R., Lopez-Alonso A., Gonzalez R., Varela H. Pericytes as a supplementary source of osteoblasts in periosteal osteogenesis. Clin Orthop. 275:1992;280-286.
6. Hashimoto J., Takaoka K., Yoshikawa H., Miyamoto S., Suzuki S., Ono K. Preservation of ectopically induced bone in the mouse by estradiol. Bone. 12:1991;249-255.
7. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 348:1990;555-557.
8. Ishidou Y., Kitajima I., Obama H., Maruyama I., Murata F., Imamura T., Yamada N., ten Dijke P., Miyazono K., Sakou T. Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation. J Bone Miner Res. 10:1995;1651-1659.
9. Kusaka M., Sudo K., Matsutani E., Kozai Y., Marui S., Fujita T., Ingber D., Folkman J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor. Br J Cancer. 69:1994;212-216.
10. Mori S., Ueda T., Kuratsu S., Hosono N., Izawa K., Uchida A. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer. 61:1995;148-152.
11. Nakahara H., Yoshikawa H., Takaoka K., Ono K. Effects of ethane-1-hydroxy-1, 1-diphosphonate on ectopic bone formation induced by murine osteosarcoma-derived bone-inducing substance. Bone. 7:1986;229-233.
12. Plasmans C. M. T., Kuypers W., Slooff T. J. J. H. The effect of ethane-1-hydroxy-1, 1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop. 132:1978;233-243.
13. Reddi A. H. Endochondral bone development is a cascade. Brighton C. T., Friedlaender G., Lane J. M. Bone Formation and Repair. 1994;147-166 American Academy of Orthopaedic Surgeons.
14. Rhinelander F. W., Baragry R. A. Microangiography in bone healing. I. Undisplaced closed fractures. J Bone J Surg. 44-A:1962;1273-1298.
15. Schor A. M., Canfield A. E., Sutton A. B., Arciniegas E., Allen T. D. Pericyte differentiation. Clin Orthop. 313:1995;81-91.
16. Takaoka K., Koezuka M., Nakahara H. Telopeptide-depleted bovine skin collagen as a carrier for bone morphogenetic protein. J Orthop Res. 9:1991;902-907.
17. ten Dijke P., Yamashita H., Sampath T. K., Reddi A. H., Estevez M., Riddle D. L., Ichijo H., Heldin C. H., Miyazono K. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem. 269:1994;16985-16988.
18. Trueta J. The role of the vessels in osteogenesis. J Bone J Surg. 45-B:1963;402-418.
19. Yamashita H., ten Dijke P., Heldin C.-H., Miyazono K. Bone morphogenetic protein receptors. Bone. 19:1996;569-574.
20. Yoshikawa H., Hashimoto J., Masuhara K., Takaoka K., Ono K. Inhibition by tumor necrosis factor of induction of ectopic bone formation by osteosarcoma-derived bone-inducing substance. Bone. 9:1988;391-396.